Colon and rectal cancer, colorectal cancer, is the third most common form of cancer in the world after prostate and breast cancer. The number of affected patients is expected to grow by approximately 50 percent worldwide, to more than 2.7 million new cases by 2030. The increase is primarily attributable to an aging population, urbanization, increased incidence of western lifestyle factors such as obesity and smoking, and more widespread screening.
Our initial market, rectal cancer, constitutes about a third of the total colorectal cancer market. Worldwide, this corresponds to about 600,000 cases annually. In Sweden, approximately 2,000 patients develop rectal cancer every year.
The total available global rectal cancer market is estimated to be worth approximately SEK 6-12 billion, under the assumption that fees of TSEK 10-20 are charged for each examination through the sale of single-use items.